LION Eye Group Signs Supplier Agreement With ABB Optical Group

By Staff
Thursday, September 24, 2020 12:30 AM NEW YORK—LION Eye Group, a network of independent optometry practices that utilizes various key initiatives and protocols across strategic and non-clinical operational disciplines to increase provider profitability, entered into a master service agreement with ABB Optical Group.

Bausch Health to Acquire Option to Purchase Assets of Allegro Ophthalmics

By Staff
Tuesday, September 22, 2020 12:27 AM LAVAL, Quebec and SAN JUAN CAPISTRANO, Calif.— Bausch Health Companies and Bausch + Lomb, its leading global eye health business, and Allegro Ophthalmics LLC,  a privately held biopharmaceutical company, announced Monday that Bausch Health (through its affiliate) has entered into an agreement to acquire an option to purchase all ophthalmology assets of Allegro.

Sen. Boozman Introduces Contact Lens Rule Modernization Act

By Staff
Monday, September 21, 2020 12:36 AM ALEXANDRIA, Va.—In an effort to offset language in the FTC’s updated Contact Lens Rule, Sen. John Boozman (R-Ark.) last week introduced in the U.S. Senate the Contact Lens Rule Modernization Act,  which would eliminate the use of robocalls to verify contact lens prescriptions, according to a statement by the Health Care Alliance for Patient Safety (APS). The bill, which APS endorsed, is co-sponsored by Sen. Roger Wicker (R-Miss.), Jim Inhofe (R-Okla.) and Sen. Rand Paul (R-Ky.)

CooperCompanies Notes Positive ‘Momentum’ Trend in July-August, But Overall Sales Slip in Third Quarter

By Staff
Friday, September 4, 2020 12:27 AM SAN RAMON, Calif.—Citing the ongoing impact of COVID-19, CooperCompanies (NYSE: COO) on Thursday reported that its third-quarter revenue decreased 15 percent year-over-year to $578.2 million, with CooperVision (CVI) revenue falling 12 percent to $449.3 million and CooperSurgical (CSI) revenue dropping 24 percent to $128.9 million.

CooperVision Taps Sarah Michelle Gellar as Spokeswoman to Increase Awareness of Myopia Management and Brilliant Futures Program

By Staff
Thursday, August 27, 2020 12:24 AM SAN RAMON, Calif.—CooperVision, a global leader in myopia management, announced Wednesday that popular U.S. television actress and producer Sarah Michelle Gellar will be the spokeswoman for its Brilliant Futures Myopia Management Program.  

CooperVision Promotes Melissa Kiewe to Vice President, North America Marketing

By Staff
Wednesday, August 26, 2020 12:18 AM SAN RAMON, Calif.—CooperVision has appointed Melissa Kiewe vice president, North America marketing, according to an announcement from the company. She is responsible for overseeing all regional marketing strategies and demand creation initiatives, including product launches, programs and promotions. She succeeds Simon Seshadri, who was promoted to the position of senior vice president, global marketing in June. Kiewe joined CooperVision in 2016 as senior director, customer marketing, for which she led the development of multifaceted marketing programs, marketing communications initiatives, and national and customer brand product launches.

‘FTC at Odds With Congress’ Around New Contact Lens Rule

By Staff
Thursday, August 20, 2020 12:24 AM ALEXANDRIA, Va.—The Health Care Alliance for Patient Safety (APS) reacted strongly this week after the Federal Trade Commission (FTC) moved to publish the new Contact Lens Rule in the Federal Register. The new CL Rule was posted for public inspection on Friday, Aug. 14 and published in the Federal Register on Monday, Aug. 17. As a result of this federal notice, the controversial changes to the CL Rule will now go into effect 60 days after the official publication date, according to APS.

U.S. Optometry Schools Invited to Certify for CooperVision’s Brilliant Futures Myopia Management Program

By Staff
Friday, August 14, 2020 12:18 AM SAN RAMON, Calif.—The U.S. optometric academic community can now access the online certification curriculum for CooperVision’s Brilliant Futures Myopia Management Program featuring MiSight 1 day contact lenses.

Patient Safety Alliance Says Congressional Members Call for ‘Action to Remedy FTC’s Final Contact Lens Rule’

By Staff
Monday, August 10, 2020 12:27 AM ALEXANDRIA, Va.—The Health Care Alliance for Patient Safety   (APS) on Friday said it applauded members of the U.S. House and Senate for letters sent to respective chamber leadership calling for a legislative remedy to the FTC’s recently issued final Contact Lens Rule. The controversial CL rule, which was released in late June, has drawn the ire of several contact lens manufacturers and the American Optometric Association (AOA), as VMAIL reported. According to APS, the bipartisan letters sent to the leadership call for legislative action to be included in COVID-19 relief legislation.

CooperVision Acquires GP Specialists, Expanding Specialty EyeCare Business and Ortho-K Options

By Staff
Monday, August 10, 2020 12:21 AM SAN RAMON, Calif.—CooperVision has acquired C&E GP Specialists Inc., the well-known customized orthokeratology contact lens manufacturer and distributor, according to an announcement on Friday. The move further expands CooperVision’s Specialty EyeCare business and its leadership in addressing the increasing severity and prevalence of myopia. The terms of the transaction were not disclosed. 

Bausch Health Announces Plan To Spin Off Its Eye Health Business Into an Independent Public Company

By Staff
Thursday, August 6, 2020 8:55 AM LAVAL, Quebec—Bausch Health Companies Inc.  (NYSE/TSX: BHC) this morning announced a plan to spin off its leading Bausch + Lomb eye health business into an independent publicly traded entity separate from the remainder of Bausch Health. The spinoff will establish two separate companies, including a fully integrated, pure play eye-health company built on the iconic Bausch + Lomb brand and long history of innovation. The remaining Bausch Health company would be a diversified pharmaceutical company with leading positions in gastroenterology, aesthetics/dermatology, neurology and international pharmaceuticals, according to Thursday’s announcement.

CooperVision Names Rajeev Garg, PhD, as Global Head of Myopia Management Strategy

By Staff
Tuesday, August 4, 2020 12:24 AM SAN RAMON, Calif.—CooperVision on Monday announced the appointment of Rajeev Garg, PhD, as global head of myopia management strategy. In this newly created role, he leads various myopia-related initiatives, including market development, acquisitions and joint ventures, technology licensing, and lifecycle management in this growing segment of vision care. Garg brings more than 20 years of experience in driving innovation and growth in health care, including optometry and ophthalmology. He most recently served as executive director, surgical marketing at Bausch + Lomb, and previously held senior marketing roles within Johnson & Johnson’s cataract, contact lens and sterilization businesses. Earlier in his career, he focused on pharmaceutical development at Abbott and Merck.

Johnson & Johnson Vision Receives FDA’s Breakthrough Device Designation

By Staff
Tuesday, July 28, 2020 12:27 AM JACKSONVILLE, Fla. – Johnson & Johnson Vision has received the FDA’s “breakthrough device” designation for its myopia control lens, company executives noted on a recent conference call with securities analysts following the announcement of second-quarter financial results. Chris DelOrefice, Johnson & Johnson’s vice president for investor relations, noted the FDA’s action on the company’s myopia lens on the July 16 conference call.

CooperVision Announces Recipients of National Optometric Association Future Contact Lens Leader Scholarships

By Staff
Monday, July 20, 2020 12:21 AM SAN RAMON, Calif.—In support of the education of future eyecare professionals, CooperVision and the National Optometric Association (NOA) have awarded three $1,000 scholarships to exceptional optometry students with a high interest in contact lenses.

Citing Negative Impact of COVID-19, Johnson & Johnson Reports That Second-Quarter Sales Declined 10.8 Percent

By Staff
Friday, July 17, 2020 12:24 AM NEW BRUNSWICK, N.J.—Johnson & Johnson (NYSE: JNJ) noted Thursday the negative impact of COVID-19 when it reported second-quarter results showing a sales decline of 10.8 percent (a decline of 9 percent on an operational basis) on a company-wide basis.